Emergent
Highly Engaged Employees

Q: What industry does Emergent belong to?

Emergent is in the industry of: Blood & Organ Banks , Manufacturing , Pharmaceuticals

Blood & Organ Banks · Maryland, United States · 501-1,000 Employees

View Company Info for Free

Overview

Headquarters

400 Professional Dr Ste 400, Gaithersbur...

Phone Number

(240) 631-3200

Website

www.emergentbiosolutions.com

Revenue

$676.8 Million

Stock Symbol

EBS

Industry

Research & Development

ZI Rank: 24

Signal Type

Dec

Jan

Feb

Mar

Apr

May

ZI Rank

Emergent’s Company Summary

Emergent BioSolutions Inc., operating as Emergent, is a life sciences company established in 1998, dedicated to providing preparedness and response solutions for public health threats. Positioned within the Biotechnology, Pharmaceuticals, and Healthcare industries, Emergent develops and manufactures critical medical countermeasures. Its product portfolio includes NARCAN Nasal Spray for opioid overdose, Vaxchora for cholera prevention, Vivotif for typhoid fever, and vaccines such as BioThrax for anthrax and ACAM2000 for smallpox. The company also offers treatments for inhalational anthrax (CYFENDUS), botulism (BAT), and Ebola (Ebanga), alongside decontamination kits and auto-injectors for chemical warfare agents. Emergent also provides contract development and manufacturing services, including drug substance and product manufacturing, packaging, and technology transfer.

With a workforce of 500-1,000 employees spread across 10 locations, Emergent maintains a substantial operational presence. The company's strategic focus on public health preparedness is underscored by its development of novel therapeutics for diseases like Lassa fever and Marburg virus disease, as well as its work on broad-spectrum influenza vaccines. Learn about Emergent's global headquarters for detailed geographic insights into its operations. This extensive range of products and services positions Emergent as a vital contributor to national and global health security initiatives, addressing both deliberate and naturally occurring health crises.

Emergent reported a revenue of $676.8M. The company operates in a competitive landscape with numerous biotechnology and pharmaceutical firms. Its funding history includes a stock issuance in 2006. The company's commitment to innovation and its broad product pipeline are key differentiators. Meet Emergent's team to understand the leadership driving these critical publicView more...

AI for GTM

The summary is generated by AI and may contain inaccuracies. Verify critical information with official sources.

About Emergent

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; RRead more

Is this data correct?

View contact profiles from Emergent

Popular SearchesEmergent Biosolutions IncEmergent BiosolutionsEmergent Bio SolutionsEmergentbiosolutionsEmergent BioDefense Operations Lansing LLCSIC Code 28,283NAICS Code 32,325Ticker NYSE: EBSShow more

Emergent Org Chart

Phone

Howard Anderson

Senior Vice President and Chief Information O...

Phone

Michelle Pepin

Chief Human Resources Officer

Phone

Kelvin Lim

President - ESMS

Phone

Simon Lowry

Chief Medical Officer Head of Research & Deve...

Phone

Get the full picture

U. Cw

Chief Information Security Officer

Phone

Get the full picture

Is Emergent your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Website visits: Recent activity has been detected on your website

Emergent, which may be a good buyer, showed buying intent in Masked Content Topic

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Click to see if Emergent had a recent Job posting/layoffs

Congratulate Masked Content for being promoted to Masked Content at Emergent

Product Launch: Get notified when Emergent launches new products

Earning: See what the market has to say on Emergent recently announced quarterly report

Check if Emergent has recently received funding, and reach out quickly before it becomes old news!

Funding: Get notified immidiatlly once Emergent has new funding data

Check out if Emergent is spiking on competitors!

Recommended Actions

Introduce yourself to Masked Content, who has shown a strong intent to purchase lately

Find 3 more new buyers

Compare Similar Companies to Emergent

Compare insights from companies similar to Emergent, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Emergent

$676.8M

501-1,000

Public

$62.5M

1998

Howard AndersonSenior Vice President and Chief Information Officer

Celltrion

$2B

1K - 5K

Public

2002

Younghwan KimDivision Chief Financial Officer

Moderna

$1.9B

1K - 5K

Public

$8.1B

2010

Stéphane BancelCEO

ADMA Biologics

$510.2M

501-1,000

Public

$462.6M

2004

Adam GrossmanFounder, President & CEO

Dendreon

$255.7M

501-1,000

Private

$50M

1992

Charles OlsonChief Operating Officer

Abzena

$112.7M

201-500

Private

$113.6M

2009

Shawn O'BrienChief Operating Officer

Center for Biologics Eval...

$25.7M

201-500

Private

Sheryl Lard-WhitefordAssociate Director, Product Management

View Email Formats for Emergent

Explore Emergent executive and leadership team.

Among all Healthcare Services companies

Low Activity

High Activity

Activity Insights

Emergent is experiencing low activity levels compared to other companies in the Healthcare Services sector.

What does this means?

Emergent is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Emergent.

Emergent financials insights

Gather financial insights about Emergent, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2006

Stock Offering

$62.5M

See All Emergent's Financials Insights

Emergent Tech Stack

A closer look at the technologies used by Emergent

See more technologies

Most Recent Scoops

Open Position

Emergent is currently seeking a Director, Medical Affairs. (London, England, United Kingdom)

Open Position

Emergent is currently seeking a Senior HR Partner. (Canton, Massachusetts, United States)

Partnership

Project

Emergent is sponsoring an observational clinical trial focused on VA-005 clinical outcomes of VIGIV treatment for smallpox vaccination complications or vaccinia infection with Centers for Disease Control and Prevention. The trial began on August 2007 with the expected completion date of August 2028. The trial is currently expected to select participants from a predetermined population.

Laboratory Operations, Medical Research, Clinical Operations

Person-Based

Jessica Perl filed a Form 4 statement of changes in beneficial ownership on April 29.

Person-Based

See more scoops

Emergent News & Media

Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources
www.globenewswire.com
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C
www.globenewswire.com
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Emergent BioSolutions Inc. (NYSE:EBS) is one of the best pharmaceutical stocks to invest in. TheFly reported on April 30 that EBS announced that Singapore’s Health Sciences Authority approved an expanded use of ACAM2000, allowing its use in preventing mpox […]
finance.yahoo.com
Emergent BioSolutions to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:
www.globenewswire.com
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent’s recent announcement that Singapore’s Health Sciences Authority (HSA) has approved an
www.globenewswire.com

Top Blood & Organ Banks Companies

Frequently Asked Questions Regarding Emergent

What is Emergent's stock symbol?

Emergent's stock symbol is EBS

What is Emergent's official website?

Emergent's official website is www.emergentbiosolutions.com

What is Emergent's Revenue?

Emergent's revenue is $676.8 Million

What is Emergent's SIC code?

Emergent's SIC: 28,283

What is Emergent's NAICS code?

Emergent's NAICS: 32,325

How many employees does Emergent have?

Emergent has 501-1,000 employees

What industry does Emergent belong to?

Emergent is in the industry of: Blood & Organ Banks, Manufacturing, Pharmaceuticals

What is Emergent competition?

Emergent top competitors include: Center for Biologics Evaluation and Research, Celltrion, Dendreon, ADMA Biologics

What companies has Emergent acquired?

Emergent has acquired the companies: Trubion Pharmaceuticals, Cangene, Antex Biologics, ADAPT Pharma

What technology does Emergent use?

Some of the popular technologies that Emergent uses are: Microsoft IIS, Freshservice, Zingfit, WordPress.org

What does Emergent do?

What are Emergent social media links?

Emergent Linkedin page Emergent Twitter page Emergent Facebook page

Is Emergent a public company?

Yes, Emergent is a public company and is traded under the symbol EBS

See more information about Emergent

Emergent Latest Hires and Their Positions

Emergent is expanding and recently hired new employees. Here are the latest additions to the team.

Lorna Aquino

Manager, Quality Assurance

Joined Feb 1, 2026

Phone

Danielle Rhoda

Head Site Director, Human Resources

Joined Feb 1, 2026

Phone

Yaffet Menna

Corporate Development

Joined Jan 1, 2026

Phone

La-Kia Kommeren

Packaging Technician

Joined Jan 1, 2026

Phone

Sell Smarter. Win Faster.

Level up your game to ZoomInfo Copilot, intuitive AI that turns your data and high-quality ZoomInfo data into an unfair advantage for your go-to-market teams.